Kalypsys Inc. announced today that it has raised $100 million in a Series C financing. Tavistock Life Sciences, one of Kalypsys' previous investors, led the round with an $89 million contribution. Previous investors Sprout Group, CMEA Ventures and KT Venture Group participated in the round.

The company will use the proceeds to fund its broad range of preclinical and clinical programs in the areas of cardiovascular/metabolic diseases, pain/inflammation and oncology.

INFO SOURCES

Kalypsys Inc.

FIRMS

Kalypsys is a San Diego-based clinical-stage pharmaceutical company that is changing the way drugs are discovered and developed. Unmatched from idea to clinical proof, Kalypsys seamlessly integrates its scientific expertise and technologies to develop small molecule drugs in a fast, efficient and effective manner. The company's discovery and clinical pipeline consists of drugs that target cardiovascular/metabolic diseases, pain/inflammation and oncology. In addition to focusing on its own products, Kalypsys partners with top-tier pharmaceutical companies to rapidly advance the identification, development and commercialization of new therapeutics.

LINKED TO

Kalypsys is Linked to: 5AM Ventures, Aravis Ventures, CMEA Ventures, Innovis, Invemed Associates, KT Venture Group, Novartis BioVenture Fund, Sprout Group and Tavistock Life Sciences.

NOTE

The financing increases the total private equity that Kalypsys has raised to $172 million since February 2002.

BOARD

 

Name	Affilation
August M. Watanabe, MD	Chairman of the Board of Kalypsys
Kenneth Langone	Chairman, and CEO of Invemed Associates LLC
John Diekman, PhD	Managing Partner of 5AM Ventures
Shehan Dissanayake, PhD	CEO of Tavistock Life Sciences
Vijay Lathi	Managing Director of New Leaf Ventures Partners
Philip Needleman, PhD	-
John McKearn, PhD	Chief Executive Officer, President
Isy Goldwasser	President and Chief Operating Officer of Symyx Technologies